Trial Profile
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CPIT001
- 16 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 May 2024.
- 16 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 May 2024.
- 24 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.